Sangamo Therapeutics, Inc.
SGMOQ Healthcare Biotechnology
Sangamo Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $39.6 million, down 31.6% from fiscal 2024. In the quarter to March 2026, revenue fell 77.6%, EPS grew 42.9% and free cash flow grew 26.2%, each against the same quarter a year earlier.
Follow SGMOQ
Sangamo Therapeutics, Inc. (SGMOQ) Altman Z-score
Sangamo Therapeutics, Inc.'s Altman Z-score for fiscal 2025 is −43.35, in the distress zone (below 1.81).
Altman Z-score, annual
Embed this chart
Annual newest first
| Period | Altman Z-score | Change (points) |
|---|---|---|
| FY2025 | −43.35 | (21.45) |
| FY2024 | −21.89 | (6.60) |
| FY2023 | −15.29 | (12.94) |
| FY2022 | −2.35 | (2.14) |
| FY2021 | −0.21 | (2.24) |
| FY2020 | 2.02 | 0.47 |
| FY2019 | 1.55 | (0.49) |
| FY2018 | 2.04 | (3.64) |
| FY2017 | 5.69 | 4.00 |
| FY2016 | 1.68 | (11.88) |
How fiscal 2025’s score is made up
| Component | This year | Year before | Result | Points |
|---|---|---|---|---|
| Working capital / total assets | (0.11) | — | −0.13 | |
| Retained earnings / total assets | (27.24) | — | −38.13 | |
| EBIT / total assets | (2.03) | — | −6.70 | |
| Market value of equity / total liabilities | 1.59 | — | 0.95 | |
| Sales / total assets | 0.66 | — | 0.66 | |
| Altman Z-score | Distress zone | −43.35 | ||
| Z″ Variant for non-manufacturing and asset-light companies (drops the sales/assets term, uses book equity) | Distress zone | −103.36 | ||
How the Altman Z-score works
Z = 1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets (Altman, 1968). The market value of equity is the close on the last trading day of the fiscal year times weighted basic shares.
Z″ = 6.56 × working capital ÷ total assets + 3.26 × retained earnings ÷ total assets + 6.72 × EBIT ÷ total assets + 1.05 × book equity ÷ total liabilities (Altman, Hartzell and Peck, 1995), the variant for non-manufacturing and asset-light companies.
| Zone | Z | Z″ |
|---|---|---|
| Safe zone | above 2.99 | above 2.60 |
| Grey zone | 1.81–2.99 | 1.10–2.60 |
| Distress zone | below 1.81 | below 1.10 |
Not worked out for banks, insurers and REITs, whose balance sheets the model does not describe, nor when a figure is missing or there is no share price in the week to the fiscal year end.
Altman Z-score against peers
| Company | Altman Z-score |
|---|---|
| GRCE Grace Therapeutics, Inc. compare | 3.3× |
| VERU Veru Inc. compare | −5.8× |
| CELU Celularity, Inc. compare | −15.2× |
| SER Serina Therapeutics, Inc. compare | −22.1× |
| SGMOQ Sangamo Therapeutics, Inc. | −43.3× |
| ANVS Annovis Bio, Inc. compare | — |
| ALDX Aldeyra Therapeutics, Inc. compare | — |
| DWTX Dogwood Therapeutics, Inc compare | — |
| TIL Instil Bio, Inc. compare | — |
What Altman Z-score is
The Altman Z-Score weighs working capital, retained earnings, operating profit, market value and sales against assets and debts to gauge the risk of distress.
1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets